Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Mar;126(3):423–435. doi: 10.1111/j.1365-2567.2008.02910.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Journal compilation © 2009 Blackwell Publishing Ltd

PMC Copyright notice

(a) Cytotoxicity of purified CD3⁺ CD56⁺ (▀) and CD3⁺ CD56⁻ cells (•) against acute myeloid leukaemia (AML) targets were abrogated when the human leucocyte antigen (HLA) class I molecules on the target cells were blocked by the W6/32 monoclonal antibody (mAb; □,○). Figure shows one representative assay. Eight comparison sets were performed for the CD3⁺ CD56⁺ subset, P < 0·05 in seven out of eight sets. Eight comparison sets were performed for the CD3⁺ CD56⁻ subset, P < 0·05 for all eight sets. Histograms show isotype control (left) and HLA class I expression on blasts without (middle) and with W6/32 blocking (right) respectively, of one representative assay. (b) Cytotoxicity of the CD3⁺ CD56⁺ cells (▀) and CD3⁺ CD56⁻ cells (•) was enhanced when HLA class I molecules on the AML target cells were up-regulated by preincubation with interferon-γ (IFN-γ; □ and ○, respectively). Figure shows one representative assay of two comparison sets carried out for both CD3⁺ CD56⁺ and CD3⁺ CD56⁻ subsets, P < 0·05 for both. Histograms show isotype control (left) and HLA class I expression on blasts without (middle) and with preincubation with IFN-γ (right) respectively, of one representative assay. (c) Cytotoxicity of the CD3⁺ CD56⁺ cells (▀) and CD3⁺ CD56⁻ cells (•) was inhibited when the CD3/T-cell receptor (TCR) complexes on the effector cells were blocked by a TCR-blocking mAb T10B9. The figure shows one representative assay. Four comparison sets were made for the CD3⁺ CD56⁺ subset, P < 0·05 in three out of four sets. Four comparison sets were made for the CD3⁺ CD56⁻ subset, P < 0·05 for all. Histograms show isotype control (left) and TCR expression on cytokine-induced killer cells without (middle) and with T10B9 blocking (right) respectively, of one representative assay. (d) Cytotoxicity of the CD3⁺ CD56⁺ cells (▀) and CD3⁺ CD56⁻ cells (•) was enhanced when the CD3/TCR complexes on the effector cells were either stimulated with OKT3 (Δ) or with a stimulating anti-TCR mAb (□). Two comparison sets were carried out for the CD3⁺ CD56⁺ subset and three comparison sets for the CD3⁺ CD56⁻ subset, P < 0.05 for all. (e) Mean fluorescent intensity of degranulation marker CD107a over time after ligation with OKT3. There were three samples at serial time-points: 0 min (□), 30 min (), 60 min (), 120 min (), 240 min (▀).

Inline graphic — (a) Cytotoxicity of purified CD3⁺ CD56⁺ (▀) and CD3⁺ CD56⁻ cells (•) against acute myeloid leukaemia (AML) targets were abrogated when the human leucocyte antigen (HLA) class I molecules on the target cells were blocked by the W6/32 monoclonal antibody (mAb; □,○). Figure shows one representative assay. Eight comparison sets were performed for the CD3⁺ CD56⁺ subset, P < 0·05 in seven out of eight sets. Eight comparison sets were performed for the CD3⁺ CD56⁻ subset, P < 0·05 for all eight sets. Histograms show isotype control (left) and HLA class I expression on blasts without (middle) and with W6/32 blocking (right) respectively, of one representative assay. (b) Cytotoxicity of the CD3⁺ CD56⁺ cells (▀) and CD3⁺ CD56⁻ cells (•) was enhanced when HLA class I molecules on the AML target cells were up-regulated by preincubation with interferon-γ (IFN-γ; □ and ○, respectively). Figure shows one representative assay of two comparison sets carried out for both CD3⁺ CD56⁺ and CD3⁺ CD56⁻ subsets, P < 0·05 for both. Histograms show isotype control (left) and HLA class I expression on blasts without (middle) and with preincubation with IFN-γ (right) respectively, of one representative assay. (c) Cytotoxicity of the CD3⁺ CD56⁺ cells (▀) and CD3⁺ CD56⁻ cells (•) was inhibited when the CD3/T-cell receptor (TCR) complexes on the effector cells were blocked by a TCR-blocking mAb T10B9. The figure shows one representative assay. Four comparison sets were made for the CD3⁺ CD56⁺ subset, P < 0·05 in three out of four sets. Four comparison sets were made for the CD3⁺ CD56⁻ subset, P < 0·05 for all. Histograms show isotype control (left) and TCR expression on cytokine-induced killer cells without (middle) and with T10B9 blocking (right) respectively, of one representative assay. (d) Cytotoxicity of the CD3⁺ CD56⁺ cells (▀) and CD3⁺ CD56⁻ cells (•) was enhanced when the CD3/TCR complexes on the effector cells were either stimulated with OKT3 (Δ) or with a stimulating anti-TCR mAb (□). Two comparison sets were carried out for the CD3⁺ CD56⁺ subset and three comparison sets for the CD3⁺ CD56⁻ subset, P < 0.05 for all. (e) Mean fluorescent intensity of degranulation marker CD107a over time after ligation with OKT3. There were three samples at serial time-points: 0 min (□), 30 min (), 60 min (), 120 min (), 240 min (▀).